"""
Question: 1101 

Evidence: We herein report the first efficacy and safety data of a randomized, clinical switch trial of once-daily DTG in combination with boosted DRV in pretreated patients with HIV-1 who have been suppressed for at least 6 months. Switching to DTG + bDRV was noninferior to continuing 3DR in subjects already treated with bDRV.

Rationale: The paper explicitly states it is the first report of efficacy and safety data for this randomized switch trial, indicating the data were previously unpublished.

Answer: Yes
"""

"""
Question: 1102 

Evidence: Resistance testing was performed at the discretion of the investigator according to the local guidelines and at any time of confirmed virologic failure, defined as HIV RNA >200 copies/mL in 2 consecutive measures. No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: The study mentions resistance testing could occur if failure happened, but it reports no failures and provides no sequence data or analyses, indicating HIV sequences were not reported.

Answer: No
"""

"""
Question: 1103 

Evidence: DUALIS, a randomized, open-label, phase 3b, noninferiority clinical trial, compared the switch to DTG + bDRV (2DR) with continuation of 2 nucleoside reverse transcriptase inhibitors (2NRTI) + bDRV (3DR). No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: The paper describes a clinical trial without any laboratory in vitro passage experiments; nothing in the methods or results refers to in vitro passage studies.

Answer: No
"""

"""
Question: 1104 

Evidence: We herein report the first efficacy and safety data of a randomized, clinical switch trial of once-daily DTG in combination with boosted DRV. No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: The focus is on clinical efficacy/safety; there are no descriptions of in vitro susceptibility assays or novel susceptibility measurements reported.

Answer: No
"""

"""
Question: 2101 

Evidence: Resistance testing was performed at the discretion of the investigator according to the local guidelines and at any time of confirmed virologic failure. No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: The paper does not present any sequence data or database submissions; no GenBank accession numbers are provided.

Answer: No
"""

"""
Question: 2102 

Evidence: Resistance testing was performed at the discretion of the investigator according to the local guidelines and at any time of confirmed virologic failure. No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: Because no sequence data were reported, no GenBank accessions (of any type) are provided.

Answer: No
"""

"""
Question: 2103 

Evidence: Resistance testing was performed at the discretion of the investigator according to the local guidelines and at any time of confirmed virologic failure. No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: The paper does not list any accession numbers; therefore none can be provided.

Answer: NA
"""

"""
Question: 2202 

Evidence: Numbers of historic genotypic resistance testing did not differ between the 2 groups and were available in 84 (64.1%) subjects in the 2DR group and 83 (62.9%) in the 3DR group; 20.9% in the 2DR group and 11.0% in the 3DR group had a history of ≥2 NRTI and ≥2 PI changes, respectively. Relevant rates of NRTI, non-NRTI, and major PI resistance--associated mutations (RAMs) were observed in 9.9% vs 9.1%, 15.3% vs 13.6%, and 3.8% vs 3.0% of the 2DR and 3DR groups, respectively.

Rationale: The paper summarizes historical resistance findings by rates but does not provide lists of mutations for individual sequenced isolates.

Answer: No
"""

"""
Question: 2301 

Evidence: We herein report the first efficacy and safety data of a randomized, clinical switch trial of once-daily DTG in combination with boosted DRV in pretreated patients with HIV-1. Investigators enrolled subjects aged ≥18 years with documented HIV-1 infection.

Rationale: The species is explicitly stated as HIV-1.

Answer: HIV-1
"""

"""
Question: 2302 

Evidence: Investigators enrolled subjects aged ≥18 years with documented HIV-1 infection. No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: The paper does not report any viral subtyping or sequence data; subtypes are not provided.

Answer: NA
"""

"""
Question: 2303 

Evidence: Resistance testing was performed at the discretion of the investigator according to the local guidelines and at any time of confirmed virologic failure. No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: No genes were sequenced/reported in the study results.

Answer: NA
"""

"""
Question: 2304 

Evidence: Resistance testing was performed at the discretion of the investigator according to the local guidelines and at any time of confirmed virologic failure. No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: There are no reported HIV pol sequence results in the paper.

Answer: No
"""

"""
Question: 2401 

Evidence: The DUALIS study is a randomized, open-label, multicenter, noninferiority, phase 3 trial conducted at 27 active study centers in Germany. Resistance testing was performed at the discretion of the investigator according to the local guidelines and at any time of confirmed virologic failure.

Rationale: No sequences were reported; therefore, geographic origins of sequences cannot be provided.

Answer: NA
"""

"""
Question: 2402 

Evidence: Between July 31, 2015, and June 6, 2017, PWH (subjects) at the dedicated centers were screened for eligibility. Resistance testing was performed at the discretion of the investigator according to the local guidelines and at any time of confirmed virologic failure.

Rationale: The paper does not report sequenced samples; hence years of sequenced sample collection are not applicable.

Answer: NA
"""

"""
Question: 2502 

Evidence: Resistance testing was performed at the discretion of the investigator according to the local guidelines and at any time of confirmed virologic failure. No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: Sequencing methods are not described because no sequencing results were reported; whether Sanger was used cannot be determined.

Answer: NA
"""

"""
Question: 2503 

Evidence: Resistance testing was performed at the discretion of the investigator according to the local guidelines and at any time of confirmed virologic failure. No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: The paper does not describe NGS use or any sequencing method; thus it cannot be determined.

Answer: NA
"""

"""
Question: 2504 

Evidence: Resistance testing was performed at the discretion of the investigator according to the local guidelines and at any time of confirmed virologic failure. No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: Because no sequencing was reported, there is no information on cloning prior to sequencing.

Answer: NA
"""

"""
Question: 2505 

Evidence: Resistance testing was performed at the discretion of the investigator according to the local guidelines and at any time of confirmed virologic failure. No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: The study does not report single-genome sequencing.

Answer: NA
"""

"""
Question: 2506 

Evidence: Resistance testing was performed at the discretion of the investigator according to the local guidelines and at any time of confirmed virologic failure. No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: There is no report of molecular cloning in this clinical trial report.

Answer: NA
"""

"""
Question: 2601 

Evidence: Resistance testing was performed at the discretion of the investigator according to the local guidelines and at any time of confirmed virologic failure. No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: The paper does not report any plasma HIV sequence results.

Answer: No
"""

"""
Question: 2602 

Evidence: Resistance testing was performed at the discretion of the investigator according to the local guidelines and at any time of confirmed virologic failure. No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: The paper does not report PBMC HIV sequencing results.

Answer: No
"""

"""
Question: 2603 

Evidence: Resistance testing was performed at the discretion of the investigator according to the local guidelines and at any time of confirmed virologic failure. No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: Since no sequencing was reported, the number of plasma virus sequences is not available.

Answer: NA
"""

"""
Question: 2604 

Evidence: Resistance testing was performed at the discretion of the investigator according to the local guidelines and at any time of confirmed virologic failure. No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: No PBMC sequencing was reported; therefore, the number is not available.

Answer: NA
"""

"""
Question: 2605 

Evidence: Resistance testing was performed at the discretion of the investigator according to the local guidelines and at any time of confirmed virologic failure. No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: As no sequences were obtained or reported, it cannot be determined whether any sequences came from actively replicating virus.

Answer: NA
"""

"""
Question: 2606 

Evidence: Resistance testing was performed at the discretion of the investigator according to the local guidelines and at any time of confirmed virologic failure. No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: The study does not report any proviral DNA reservoir sequencing.

Answer: NA
"""

"""
Question: 2701 

Evidence: Investigators enrolled subjects aged ≥18 years with documented HIV-1 infection. It should be noted that the recruitment rate was lower than expected due to changes in the use of DRV-based ART.

Rationale: Only adults (≥18 years) were enrolled; no infants or children.

Answer: No
"""

"""
Question: 2702 

Evidence: The DUALIS study is a randomized, open-label, multicenter, noninferiority, phase 3 trial conducted at 27 active study centers in Germany. Written informed consent was obtained from all subjects before enrollment.

Rationale: Participants were enrolled in a clinical trial.

Answer: Yes
"""

"""
Question: 2703 

Evidence: The DUALIS study is a randomized, open-label, multicenter, noninferiority, phase 3 trial conducted at 27 active study centers in Germany. In total, 265 subjects were randomly assigned to the intervention group of DTG and boosted DRV (2DR; n = 131) or to continuation of antiretroviral therapy (3DR) with a combination of 2 NRTIs in combination with boosted DRV (n = 132) and received at least 1 dose of study drugs.

Rationale: All individuals discussed in the results were participants in the clinical trial.

Answer: Yes
"""

"""
Question: 3101 

Evidence: Resistance testing was performed at the discretion of the investigator according to the local guidelines and at any time of confirmed virologic failure. No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: The paper does not report obtaining samples for HIV sequencing; hence the number cannot be determined.

Answer: NA
"""

"""
Question: 3102 

Evidence: Resistance testing was performed at the discretion of the investigator according to the local guidelines and at any time of confirmed virologic failure. No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: There is no report that individuals underwent HIV sequencing.

Answer: NA
"""

"""
Question: 4101 

Evidence: Resistance testing was performed at the discretion of the investigator according to the local guidelines and at any time of confirmed virologic failure. No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: No HIV sequences were reported from any group, including ART-naive individuals.

Answer: No
"""

"""
Question: 4102 

Evidence: Resistance testing was performed at the discretion of the investigator according to the local guidelines and at any time of confirmed virologic failure. No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: The paper does not report HIV sequences from ART-experienced individuals.

Answer: No
"""

"""
Question: 4103 

Evidence: Resistance testing was performed at the discretion of the investigator according to the local guidelines and at any time of confirmed virologic failure. No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: Since no sequences are reported, there are none from either ART-naive or ART-experienced groups.

Answer: No
"""

"""
Question: 4104 

Evidence: Resistance testing was performed at the discretion of the investigator according to the local guidelines and at any time of confirmed virologic failure. Investigators enrolled subjects aged ≥18 years with documented HIV-1 infection, who had been virologically suppressed (plasma HIV RNA <50 copies/mL) for at least 6 months before screening and were on a stable, once-daily antiretroviral therapy consisting of ritonavir-boosted DRV in combination with 2 NRTIs.

Rationale: No sequences were obtained; thus the number from ART-naive individuals cannot be provided.

Answer: NA
"""

"""
Question: 4105 

Evidence: Numbers of historic genotypic resistance testing did not differ between the 2 groups and were available in 84 (64.1%) subjects in the 2DR group and 83 (62.9%) in the 3DR group. Moreover, ... an incomplete history of genotypic resistance documentation ...

Rationale: The paper notes incomplete historical genotypic resistance documentation and does not provide complete ART histories for all individuals.

Answer: No
"""

"""
Question: 4201 

Evidence: Numbers of historic genotypic resistance testing did not differ between the 2 groups and were available in 84 (64.1%) subjects in the 2DR group and 83 (62.9%) in the 3DR group. Relevant rates of NRTI, non-NRTI, and major PI resistance–associated mutations (RAMs) were observed ...

Rationale: The paper does not analyze or report prevalence of transmitted drug resistance; it only notes historical RAM rates without defining transmitted resistance.

Answer: No
"""

"""
Question: 4202 

Evidence: Numbers of historic genotypic resistance testing did not differ between the 2 groups and were available in 84 (64.1%) subjects in the 2DR group and 83 (62.9%) in the 3DR group. Relevant rates of NRTI, non-NRTI, and major PI resistance–associated mutations (RAMs) were observed ...

Rationale: The study does not report prevalence of pretreatment resistance; it focuses on switch efficacy and safety with limited historical resistance summaries.

Answer: No
"""

"""
Question: 4301 

Evidence: Subjects ... were on a stable, once-daily antiretroviral therapy consisting of ritonavir-boosted DRV in combination with 2 NRTIs. Subjects were randomized ... to either receive oral DTG 50 mg once daily in combination with DRV 800 mg once daily and ritonavir 100 mg daily (2DR) or continue their regimen consisting of 2 NRTIs in combination with ritonavir-boosted DRV (3DR).

Rationale: Participants received regimens including protease inhibitors (DRV/r), nucleoside reverse transcriptase inhibitors (NRTIs), and integrase inhibitor (DTG in the 2DR arm).

Answer: NRTIs, Protease inhibitors, Integrase inhibitors
"""

"""
Question: 4302 

Evidence: Subjects were randomized ... to either receive oral DTG 50 mg once daily in combination with DRV 800 mg once daily and ritonavir 100 mg daily (2DR) or continue their regimen consisting of 2 NRTIs in combination with ritonavir-boosted DRV (3DR). Switching to DTG + bDRV was noninferior to continuing 3DR ...

Rationale: The 2DR arm included the integrase inhibitor dolutegravir.

Answer: Yes
"""

"""
Question: 4303 

Evidence: Subjects ... were on a stable, once-daily antiretroviral therapy consisting of ritonavir-boosted DRV in combination with 2 NRTIs. Subjects were randomized ... to either receive oral DTG ... in combination with DRV 800 mg once daily and ritonavir 100 mg daily (2DR) or continue ... ritonavir-boosted DRV (3DR).

Rationale: Both study arms included boosted darunavir, a protease inhibitor.

Answer: Yes
"""

"""
Question: 4304 

Evidence: Subjects were randomized 1:1 ... to either receive oral DTG 50 mg ... with DRV/ritonavir (2DR) or continue 2 NRTIs + DRV/ritonavir (3DR). A switch of the NRTI backbone ... was allowed at any time during the study period at the discretion of the investigator.

Rationale: Participants received different regimens depending on randomization and NRTI backbone could change; thus not all received the same ART.

Answer: No
"""

"""
Question: 4305 

Evidence: Exclusion criteria were documented major darunavir or INSTI resistance. Subjects ... were on a stable ... regimen consisting of ritonavir-boosted DRV in combination with 2 NRTIs.

Rationale: The study did not explicitly state INSTI-naive status; only that major INSTI resistance was excluded and baseline regimens did not include INSTIs, so INSTI-naivety cannot be confirmed.

Answer: NA
"""

"""
Question: 4403 

Evidence: Time on previous ART, median (IQR), mo: 50 (27–69) in 2DR and 38 (17–65) in 3DR. 20.9% in the 2DR group and 11.0% in the 3DR group had a history of ≥2 NRTI and ≥2 PI changes, respectively.

Rationale: The paper does not provide the exact count of individuals who received more than one ART regimen; only partial indicators of prior changes are given.

Answer: NA
"""

"""
Question: 4404 

Evidence: 20.9% in the 2DR group and 11.0% in the 3DR group had a history of ≥2 NRTI and ≥2 PI changes, respectively. Time on previous ART, median (IQR), mo: 50 (27–69) vs 38 (17–65).

Rationale: While some had multiple component changes, the exact number who received more than two ART regimens is not reported.

Answer: NA
"""

"""
Question: 4405 

Evidence: 20.9% in the 2DR group and 11.0% in the 3DR group had a history of ≥2 NRTI and ≥2 PI changes, respectively. Time on previous ART varied between groups.

Rationale: Variation in prior ART changes indicates individuals did not all receive the same number of regimens.

Answer: No
"""

"""
Question: 4406 

Evidence: 20.9% in the 2DR group and 11.0% in the 3DR group had a history of ≥2 NRTI and ≥2 PI changes, respectively. Time on previous ART, median (IQR), mo: 50 (27–69) vs 38 (17–65).

Rationale: The presence of multiple prior changes for many participants shows not all individuals received only one regimen.

Answer: No
"""

"""
Question: 4501 

Evidence: In total, 263 subjects were randomized and treated (2DR n = 131, 3DR n = 132). Subjects were randomized ... to either receive oral DTG 50 mg once daily in combination with DRV 800 mg once daily and ritonavir 100 mg daily (2DR) ...

Rationale: The 2DR arm contained dolutegravir; 131 participants received DTG.

Answer: 131
"""

"""
Question: 4502 

Evidence: In total, 263 subjects were randomized and treated (2DR n = 131, 3DR n = 132). Subjects were randomized ... to either receive oral DTG ... with DRV/ritonavir (2DR) or continue 2 NRTIs + DRV/ritonavir (3DR).

Rationale: Both arms received darunavir/ritonavir; thus all 263 treated participants received darunavir.

Answer: 263
"""

"""
Question: 5101 

Evidence: Relevant rates of NRTI, non-NRTI, and major PI resistance--associated mutations (RAMs) were observed in 9.9% vs 9.1%, 15.3% vs 13.6%, and 3.8% vs 3.0% of the 2DR and 3DR groups, respectively. No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: The study provides percentages for historical RAMs by class but does not give the exact number of individuals with one or more mutations overall.

Answer: NA
"""

"""
Question: 5102 

Evidence: Exclusion criteria were documented major darunavir or INSTI resistance. No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: The study excluded major INSTI resistance at baseline and observed no emergent resistance; it does not provide counts of INSTI-resistance mutations.

Answer: NA
"""

"""
Question: 5103 

Evidence: Relevant rates of NRTI, non-NRTI, and major PI resistance--associated mutations (RAMs) were observed ... No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: The paper does not specify TDF-resistance mutations.

Answer: NA
"""

"""
Question: 5104 

Evidence: Development of treatment-emergent resistance was not observed. No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: Since no treatment-emergent resistance occurred, no INSTI-resistance mutations developed.

Answer: None
"""

"""
Question: 6101 

Evidence: We herein report the first efficacy and safety data of a randomized, clinical switch trial of once-daily DTG in combination with boosted DRV. No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: The study did not perform or report phenotypic susceptibility testing; thus no method is described.

Answer: NA
"""

"""
Question: 6102 

Evidence: We herein report the first efficacy and safety data of a randomized, clinical switch trial of once-daily DTG in combination with boosted DRV. No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: The paper does not report IC metrics such as IC50 or IC90.

Answer: No
"""

"""
Question: 6103 

Evidence: We herein report the first efficacy and safety data of a randomized, clinical switch trial of once-daily DTG in combination with boosted DRV. No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: No phenotypic susceptibility testing or fold-change data are reported.

Answer: No
"""

"""
Question: 6104 

Evidence: We herein report the first efficacy and safety data of a randomized, clinical switch trial of once-daily DTG in combination with boosted DRV. No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: No phenotypic assay was used or reported.

Answer: NA
"""

"""
Question: 6105 

Evidence: The overall tolerability of both treatment strategies was acceptable, with comparable rates of AEs. No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: The paper does not report replication capacity measurements.

Answer: No
"""

"""
Question: 6106 

Evidence: We herein report the first efficacy and safety data of a randomized, clinical switch trial of once-daily DTG in combination with boosted DRV. No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: No phenotypic susceptibility testing was performed; therefore, no drugs were tested in such assays.

Answer: NA
"""

"""
Question: 7101 

Evidence: DUALIS, a randomized, open-label, phase 3b, noninferiority clinical trial, compared the switch to DTG + bDRV with continuation of 2 NRTI + bDRV. No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: The study did not construct or analyze site-directed mutant isolates.

Answer: No
"""

"""
Question: 7102 

Evidence: DUALIS, a randomized, open-label, phase 3b, noninferiority clinical trial, compared clinical treatment strategies. No virologic failure with treatment-emergent resistance to any of the study component drugs was documented during the entire study period.

Rationale: There were no in vitro passage experiments reported.

Answer: No
"""